ReviewEnfermedades infecciosas y microbiologia clinica2019
[Use of ribavirin in viruses other than hepatitis C. A review of the evidence].
Review in Enfermedades infecciosas y microbiologia clinica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Meta-analysis of functional genomics studies reveals conserved cellular pathways required by viruses of pandemic concern.Access microbiology · 2026Article
- Safety of ribavirin in cockatiels (Nymphicus hollandicus) - a preliminary study.Scientific reports · 2025Article
- High-Pressure Polymorphism of Ribavirin.Crystal growth & design · 2025Article
- Bovine Serum Albumin Nanoparticle-Mediated Delivery of Ribavirin and Mycophenolic Acid for Enhanced Antiviral Therapeutics.Viruses · 2025Article
- Repurposing of CDK Inhibitors as Host Targeting Antivirals: A Mini- Review.Mini reviews in medicinal chemistry · 2025Review
- Synthesis of Substituted 1,2,4-Triazole-3-Thione Nucleosides UsingBiomolecules · 2024Article
- Antiviral Chemotherapy in Avian Medicine-A Review.Viruses · 2024Review
- Severe COVID-19: Drugs and Clinical Trials.Journal of clinical medicine · 2023Review
- Inhibitors of Nucleotide Biosynthesis as Candidates for a Wide Spectrum of Antiviral Chemotherapy.Microorganisms · 2022Review
- Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity.Viruses · 2022Review
- Antiviral Activity of Ribavirin againstPathogens (Basel, Switzerland) · 2021Article
- Lymphocytic Choriomeningitis-Emerging Trends of a Neglected Virus: A Narrative Review.Tropical medicine and infectious disease · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ribavirin is a molecule with antiviral activity against different viruses. In clinical practice, it has made its niche almost exclusively for the treatment of the hepatitis C virus. However, there are other diseases in which it could be of benefit and it has the advantage of being suitable for oral, intravenous and inhaled administration. We conducted a review of the indications of the main drug agencies (Spanish, European and American) and other possible indications, mainly haemorrhagic fevers and coronavirus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.